68Ga-FAPI PET/CT肿瘤分期显示非特异性淋巴结发现率低于18F-FDG PET/CT
前瞻性观察性研究中18例患者接受18F-FDG与68Ga-FAPI PET/CT扫描(中位间隔2天),淋巴结以组织病理学评估并与SUV测量比较。68Ga-FAPI PET/CT对真性淋巴结转移的准确率为94%,高于18F-FDG PET/CT的55%;68Ga-FAPI PET/CT将18F-FDG PET/CT假阳性淋巴结中的5/6(83%)判为真阴性。结论认为68Ga-FAPI PET/CT对真性淋巴结受累的准确性更高,有潜力替代18F-FDG PET/CT用于肿瘤分期。
要点
- 18F-FDG PET/CT将10例(56%)患者淋巴结评为恶性,68Ga-FAPI PET/CT评为7例(39%)。
- 真性淋巴结转移准确率:68Ga-FAPI PET/CT 94% vs 18F-FDG PET/CT 55%。
- 按病灶分析,两者肿瘤检出率相似(85/89个病灶,96%)。
核心结论
- 68Ga-FAPI PET/CT对真性淋巴结受累显示出更高的准确性,因此有潜力替代18F-FDG PET/CT用于肿瘤分期。
研究设计与样本
- 来自前瞻性观察性研究的18例患者,在中位2天(范围0-22天)内接受18F-FDG与68Ga成纤维细胞激活蛋白抑制剂(FAPI)PET/CT扫描。
- 淋巴结通过组织病理学评估,并与SUV测量结果进行比较。
主要发现
- 按患者分析,18F-FDG PET/CT与68Ga-FAPI PET/CT分别将10例(56%)与7例(39%)患者的淋巴结评为恶性。
- 真性淋巴结转移准确率分别为18F-FDG PET/CT 55% vs 68Ga-FAPI PET/CT 94%。
- 18F-FDG PET/CT扫描上6个假阳性淋巴结中的5个(83%)被68Ga-FAPI PET/CT扫描评为真阴性。
- 按病灶分析,肿瘤检出率相似(85/89个病灶,96%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonspecific lymph node uptake on 18F-FDG PET/CT imaging is a significant pitfall for tumor staging. Fibroblast activation protein α expression on cancer-associated fibroblasts and some tumor cells is less sensitive to acute inflammatory stimuli, and fibroblast activation protein-directed PET may overcome this limitation. Methods: Eighteen patients from our prospective observational study underwent 18F-FDG and 68Ga fibroblast activation protein inhibitor (FAPI) PET/CT scans within a median of 2 d (range, 0-22 d). Lymph nodes were assessed on histopathology and compared with SUV measurements. Results: On a per-patient basis, lymph nodes were rated malignant in 10 (56%) versus 7 (39%) patients by 18F-FDG PET/CT versus 68Ga-FAPI PET/CT scans, respectively, with a respective accuracy of 55% versus 94% for true lymph node metastases. Five of 6 (83%) false-positive nodes on the 18F-FDG PET/CT scans were rated true negative by the 68Ga-FAPI PET/CT scans. On a per-lesion basis, tumor detection rates were similar (85/89 lesions, 96%). Conclusion: 68Ga-FAPI PET/CT imaging demonstrated higher accuracy for true nodal involvement and therefore has the potential to replace 18F-FDG PET/CT imaging for cancer staging.
引用
- Demmert TT, Pomykala KL, Lanzafame H, et al. Oncologic Staging with 68Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than 18F-FDG PET/CT. J Nucl Med. 2023. PMID: 37734836. doi:10.2967/jnumed.123.265751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。